Neuberger High Yield Strategies Fund Inc. (NHS)

On our desk, we are viewing NHS with extreme caution despite the eye-popping 17.4% yield. When you dig into the mechanics, earnings consistently fail to cover payouts, forcing a reliance on volatile realized gains and driving persistent NAV erosion. With leverage pushing over 30% and roughly 98% of the portfolio sitting in below-investment-grade debt, the risk profile simply does not justify chasing the yield in a higher rate environment.

From a risk management standpoint, the technical picture for NHS is deteriorating. The stock recently passed below its 200-day moving average, and it trades at a wider discount to its actual NAV of roughly 7.85%. While income-focused investors might be tempted by the high distribution rate, the structural risk of capital deterioration driven by insufficient net investment income makes this fund a challenging hold.

When evaluating closed-end funds like NHS for institutional portfolios, our quantitative protocols focus heavily on earnings coverage of the distribution. In this case, the distribution isn't fully supported by net investment income, and the roughly 32.6% total leverage ratio amplifies both yield and downside volatility. Analysts recommend staying away or shifting focus unless accounts are strictly tax-advantaged and built to weather capital erosion.